DMAC
DiaMedica TherapeuticsFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Positive clinical readouts or a strategic partnership plus non-dilutive funding lead to rapid re-rating; upside driven by licensing/milestone value.
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta +0.1.
What can break
Clinical failure or need for heavy dilution compresses equity value materially; low liquidity amplifies downside.
Momentum
9
Value
42
Sentiment
0
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $0.57 · Bull $1.08 · Bear $0.17
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2025-12-13 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $15.59
Why
Momentum9 · Δ7d +4.7
Value42 · Δ7d +0.1
Sentiment0 · Δ7d 0.0
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Value · See fundamentals
Momentum
9
34% active weight
Current posture
7d trendImproving
Δ7d
+4.7
Δ21d
-1.7
Value
42
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
0
33% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
0.0
Why this grade
Composite grade F. Momentum 9.0 / Value 41.9 / Sentiment 0.0
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$314.68M
Beta
1.10
Shares Out
52.08M
P/E (TTM) · Derived
-10.0
P/S (TTM)
-
P/FCF (TTM) · Derived
-9.69
Rev YoY
-
EPS YoY
-18.4%
Gross Margin
-
Op Margin
-
Net Debt
-$44.12M
Current Ratio
10.67
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology